Pharmaceuticals

Right Brain Bio is leveraging Dassault Systèmes' powerful MEDIDATA platform to accelerate a radical new therapy that could reverse Parkinson's pathology.

Zevra Therapeutics' new data for MIPLYFFA in infants with NPC is more than a medical update; it's a key commercial milestone to widen its market.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

Soleo Health's repeat URAC award isn't just a corporate win. It signals a crucial shift where data-driven quality becomes the bedrock of a resilient system.

With a promising drug, fresh cash, and a new board member known for billion-dollar exits, Avalo Therapeutics is signaling a major strategic shift.

In a head-to-head battle, Takeda's zasocitinib showed superior skin clearance over a key competitor, signaling a potential new standard for oral therapy.

A new, fast-acting neurotoxin with a two-week lifespan just hit the market. Allergan's Boey® aims to capture hesitant consumers with a low-commitment 'trial run'.

An FDA fast-track for a devastating brain disease drug is a beacon of hope for patients and a major validation of Alphabet's long-term biotech strategy.

A new partnership between AGEPHA Pharma and Close-Up Intl reveals how AI is not just a buzzword, but a critical tool for getting vital medicines to patients.

Nippon Shinyaku and Boston Children's Hospital deepen their pact, combining corporate might with research prowess to create new therapies for rare neurology.

Insmed recruits J&J and Novartis veteran Samuele Butera to execute the multi-billion-dollar launch of BRINSUPRI and expand its respiratory franchise.

HLS Therapeutics is betting on itself with a larger share buyback. We analyze if this is a signal of deep value or a sign of limited growth opportunities.

A biopharma firm's celebrated 20% growth is now alleged to be a mirage, sparking a fraud lawsuit that questions where the line is drawn between ambition and accountability.

A new survey reveals the crippling cost of insulin, forcing millions to choose between medicine and groceries. A bipartisan bill may offer a lifeline.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?

The European Commission has approved MAVIRET for acute Hepatitis C, a move set to streamline patient care and accelerate progress against a silent epidemic.

AbbVie's blockbuster SKYRIZI wins European approval for pediatric psoriasis, unlocking a new market and offering a new standard of care to young patients.

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.

Cosmos Health secures 25M+ unit orders, projecting a $10M profit from its Greek facility. A bold manufacturing play to stabilize its finances.